Multi-Modal platform
- Drug development is time-consuming and costly, with high attrition rates in clinical development.
- While drug repurposing offers a faster path, current approaches remain fragmented and inefficient.
- Existing AI tools are siloed and lack orchestration across diverse data sources and analytical methods.
- A unified multi-modal platform is required to integrate molecular structure, gene expression, knowledge graphs, and clinical evidence.
- Bridging dry and wet lab is essential to close the gap between computational discovery and experimental validation.
End-to-End Drug Repurposing
Repurgenesis is an AI-driven biotechnology company pioneering Intelligent Orchestrating — a new paradigm that harmonizes multiple models, diverse datasets, and multi-modal mechanisms to accelerate End-to-End Drug Repurposing.
Bridging computational discovery
Through an AI-orchestrated ecosystem, Repurgenesis integrates molecular structure modeling, omics analysis, knowledge graph reasoning, and clinical evidence mining to uncover new therapeutic potentials from existing drugs — bridging computational discovery with experimental validation in one continuous, intelligent cycle.
